Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer

por Feliu, J, Vicent, J M, García-Girón, C, Constela, M, Fonseca, E, Aparicio, J, Lomas, M, Antón-Aparicio, L, Dorta, F J, Gonzalez-Baron, M
Publicado 2004

Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study

por Van Cutsem, E, Dirix, L, Van Laethem, J-L, Van Belle, S, Borner, M, Gonzalez Baron, M, Roth, A, Morant, R, Joosens, E, Gruia, G, Sibaud, D, Bleiberg, H
Publicado 2005

Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer

por Batista, N, Perez-Manga, G, Constenla, M, Ruiz, A, Carabantes, F, Castellanos, J, Gonzalez Barón, M, Villman, K, Söderberg, M, Ahlgren, J, Casinello, J, Regueiro, P, Murias, A
Publicado 2004

Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer

por Feliu, J, Castañón, C, Salud, A, Mel, J R, Escudero, P, Pelegrín, A, López-Gómez, L, Ruiz, M, González, E, Juárez, F, Lizón, J, Castro, J, González-Barón, M
Publicado 2005

XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer

por Feliu, J, Salud, A, Escudero, P, Lopez-Gómez, L, Bolaños, M, Galán, A, Vicent, J-M, Yubero, A, Losa, F, De Castro, J, de Mon, M Á, Casado, E, González-Barón, M
Publicado 2006

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

por Feliu, J, Safont, M J, Salud, A, Losa, F, García-Girón, C, Bosch, C, Escudero, P, López, R, Madroñal, C, Bolaños, M, Gil, M, Llombart, A, Castro-Carpeño, J, González-Barón, M
Publicado 2010